Clinical Trial: HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811986) titled 'HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease' on Aug. 24.

Brief Summary: This is a prospective, single-arm, exploratory Phase II clinical study evaluating the efficacy and safety of HP-001 capsules in combination with dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) with extramedullary disease (EMD).

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM)

Intervention: DRUG: HP-001

HP-001 capsules will be administered orally at a dose of 0.6 mg once daily on Days 1-10 of each 28-day treatment cycle.

DRUG: Dexamethas...